GlycoMimetics, Inc. (GLYC)
NASDAQ: GLYC · Real-Time Price · USD
0.317
-0.003 (-1.00%)
Nov 22, 2024, 4:00 PM EST - Market closed
GlycoMimetics Employees
GlycoMimetics had 35 employees as of December 31, 2023. The number of employees decreased by 4 or -10.26% compared to the previous year.
Employees
35
Change (1Y)
-4
Growth (1Y)
-10.26%
Revenue / Employee
$286
Profits / Employee
-$1,135,287
Market Cap
20.43M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Concord Medical Services Holdings | 727 |
BioXcel Therapeutics | 74 |
Enlivex Therapeutics | 71 |
American Shared Hospital Services | 31 |
Spruce Biosciences | 29 |
NeuroOne Medical Technologies | 16 |
AEON Biopharma | 10 |
NeuroBo Pharmaceuticals | 8 |
GLYC News
- 10 days ago - Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - PRNewsWire
- 16 days ago - GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - Business Wire
- 22 days ago - GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC - Business Wire
- 24 days ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders - PRNewsWire
- 24 days ago - GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Business Wire
- 24 days ago - GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint - Business Wire
- 4 months ago - GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan - Business Wire
- 6 months ago - GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - Business Wire